Natco settles patent suit with Gilead, others over Tamiflu
New Delhi: Natco Pharma and its partner Alvogen said they have settled patent infringement suit with Gilead Sciences Inc and others over Tamiflu, in a US court.
"Natco Pharma Ltd and Alvogen have settled the patent infringement suit filed by Gilead Sciences Inc, Hoffmann-La Roche Inc, F. Hoffmann-La Roche Ltd and Genentech Inc... in New Jersey District Court," Natco said in a regulatory filing.
Tamiflu is used in the treatment of bird and swine-flu infections.
Natco and Alvogen partnered on the first Abbreviated New Drug Application (ANDA) containing a paragraph IV certification filed with the US Food and Drug Administration (FDA) for generic versions of Tamiflu oral capsules (oseltamivir phosphate) of 30 mg, 45 mg and 75 mg strengths.
In March last year, USFDA had granted tentative approval to Natco for the generic oseltamivir phosphate capsules.
"Under the terms of the settlement, Natco's partner Alvogen will be able to market the oseltamivir phosphate capsules before the expiration of the pediatric exclusivity period listed... which is February 23, 2017," it added.
In 2011, Natco had challenged Gilead's patent on Tamiflu (Oseltamivir Phosphate) alleging that Gilead's patent on the drug is invalid.
Tamiflu was developed by Gilead, which receives royalties on the drug's sale from Roche Holding.
"Natco Pharma Ltd and Alvogen have settled the patent infringement suit filed by Gilead Sciences Inc, Hoffmann-La Roche Inc, F. Hoffmann-La Roche Ltd and Genentech Inc... in New Jersey District Court," Natco said in a regulatory filing.
Tamiflu is used in the treatment of bird and swine-flu infections.
Natco and Alvogen partnered on the first Abbreviated New Drug Application (ANDA) containing a paragraph IV certification filed with the US Food and Drug Administration (FDA) for generic versions of Tamiflu oral capsules (oseltamivir phosphate) of 30 mg, 45 mg and 75 mg strengths.
In March last year, USFDA had granted tentative approval to Natco for the generic oseltamivir phosphate capsules.
"Under the terms of the settlement, Natco's partner Alvogen will be able to market the oseltamivir phosphate capsules before the expiration of the pediatric exclusivity period listed... which is February 23, 2017," it added.
In 2011, Natco had challenged Gilead's patent on Tamiflu (Oseltamivir Phosphate) alleging that Gilead's patent on the drug is invalid.
Tamiflu was developed by Gilead, which receives royalties on the drug's sale from Roche Holding.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.